Key result
Treatment with pdVWF/FVIII-C achieved 100% excellent and/or good clinical efficacy for on-demand and prophylaxis treatment in patients with von Willebrand disease over 12 months.
Why the study?
This study was conducted to assess the safety and efficacy associated with long-term real-world experience of the pdVWF/FVIII-C, Fanhdi, in patients with von Willebrand disease.
Does pdVWF/FVIII-C provide safe and effective hemostasis in adult patients with von Willebrand disease?
Cohort (n=15)
Yes
Does pdVWF/FVIII-C provide safe and effective hemostasis in adult patients with von Willebrand disease?
Real-world use of pdVWF/FVIII-C in patients with von Willebrand disease is safe and highly effective for both on-demand and prophylactic treatment of bleeding.
Answers are grounded in this paper and cite their sources.
May support pdVWF/FVIII-C hemostasis in VWD; leaves open need for randomized confirmation in larger cohorts.
Introduction Plasma-derived von Willebrand factor containing FVIII concentrates (pdVWF/FVIII-C) are indicated as replacement therapy for patients with von Willebrand disease (VWD). This study assessed safety and efficacy associated with long-term real-world experience of the pdVWF/FVIII-C, Fanhdi ® , in patients with VWD. Methods This observational, prospective, post-authorization cohort study was conducted at five centers in Spain. Patients with VWD were treated with the pdVWF/FVIII-C to achieve satisfactory hemostasis for on-demand (bleeding episodes and surgical/invasive procedures) and prophylaxis treatment. Clinical efficacy was evaluated as the response to treatment in both settings. Safety parameters were assessed. Results Fifteen VWD patients received at least one dose of the pdVWF/FVIII-C and were followed for 12 months. Forty-six bleeding episodes were reported for 9 (60.0%) patients, and 6 surgical/invasive procedures for 5 (33.3%) patients. Most frequently reported bleedings were gastrointestinal (3 [33.0%] patients) and gynecological (3 [33.0%] patients). No complications nor bleeding episodes related to surgical/invasive procedures were reported. Overall clinical efficacy of treatment (including on-demand and prophylaxis) achieved 100% excellent and/or good (n = 15 patients), being excellent for 7 (46.7%) patients. There were 27 treatment-emergent adverse events in 8 (53.3%) patients, 11 serious adverse events in 3 (20.0%) patients, but none of them were drug-related. No clinical signs and symptoms of immunogenicity or thromboembolic events were reported. Conclusions This real-world evidence study confirmed the efficacy of the pdVWF/FVIII-C as on-demand and/or prophylaxis treatment in patients with bleeding episodes or surgical procedures in VWD. Fanhdi ® was well tolerated without any safety concerns.
No takes yet. Share an insight, caveat, or question.
Benítez et al. (2025) conducted a cohort in von Willebrand disease (n=15). pdVWF/FVIII-C (Fanhdi) was evaluated on Overall clinical efficacy of treatment (excellent and/or good response). Treatment with pdVWF/FVIII-C achieved 100% excellent and/or good clinical efficacy for on-demand and prophylaxis treatment in patients with von Willebrand disease over 12 months.
Synapse has enriched 10 related papers. Consider them for comparative context: